Primera Therapeutics, Inc.

Primera Therapeutics is dedicated to finding a solution for mitochondrial diseases by creating a groundbreaking gene editing platform that targets inherited mutations in mitochondrial DNA. Their pioneering approach involves using a tailored TALE-based system to precisely edit the faulty DNA within the mitochondrial genome. This innovative technique allows for the first time, precision gene editing at the mitochondrial level. With the help of strategic partners and a cutting-edge toolkit, Primera aims to rapidly develop cures for mitochondrial diseases and provide much-needed support to affected patients. The company plans to collaborate closely with organizations such as Cellectis, CHOP, Mayo Clinic, UMDF, and others to expedite the development and delivery of these cures.